Comparative Pharmacology
Head-to-head clinical analysis: MICROSUL versus SULPHRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROSUL versus SULPHRIN.
MICROSUL vs SULPHRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Its active sulfide metabolite is responsible for therapeutic effects.
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
1-2 tablets (500-1000 mg paracetamol, 65-130 mg caffeine) orally every 4-6 hours as needed, not exceeding 8 tablets (4000 mg paracetamol) per day for adults.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours; prolonged in renal impairment
2-3 hours; clinically, hepatic impairment may prolong to 5-10 hours requiring dose adjustment
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Renal: 85-90% as glucuronide and sulfate conjugates, 5-10% unchanged; biliary/fecal: <5%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic